Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

London startup raises $60M for degraders aimed at Alzheimer’s protein tau

EndpointsView source article

Part of story

Oyster Therapeutics raises $60M for brain-penetrating small molecule degraders

Brain-focused startup Oyster Therapeutics secured $60 million to advance its lead program targeting pathological tau in Alzheimer's disease, with Eli Lilly participating in the round.

Nov 15, 2026·3 sourcesNeurodegenerative diseaseAlzheimer’s & dementiaAlzheimer's diseaseBiotech innovationVenture capital fundingDrug developmentDrug discoveryBiotech startupEli Lilly
Oyster Therapeutics raises $60M for brain-penetrating small molecule degraders
00

Other sources for this story

MedCity News

Brain-Focused Startup Oyster Gets $60M to Beat the Size Problem for Small Molecule Degraders - MedCity News

BioPharma Dive

London biotech Oyster harvests $60M for tau-targeting brain drugs